Found 10 matching trials
Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age PHASE3 Infection with human papillomavirus (HPV) has been clearly established as t...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects PHASE3 Infection with human papillomavirus (HPV) has been clearly established as t...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects PHASE3 Infection with human papillomavirus (HPV) has been clearly established as t...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Female Subjects Aged >/= 26 Years PHASE3 Infection with human papillomavirus (HPV) has been clearly established as t...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Evaluation of the Immune and Safety Response of GlaxoSmithKline (GSK) Biologicals' HPV Vaccine in Healthy Indian Women PHASE3 Human papillomavirus infection has clearly been recognized as the cause of ...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Human Papillomavirus Vaccine Safety & Immunogenicity Trial in Healthy Young Adult Women With HPV Vaccine (GSK1674330A) PHASE1 Infection with human papillomavirus (HPV) has been clearly established as t...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus (HPV) Vaccine With Other Vaccines in Healthy Female Subjects PHASE3 Infection with human papillomavirus (HPV) has been clearly established as t...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Human Papillomavirus (HPV) Vaccine (Cervarix TM) Efficacy, Immunogenicity & Safety Trial in Adult Japanese Women With GSK Biologicals HPV-16/18 Vaccine PHASE2 Infection with human papillomavirus (HPV) has been clearly established as t...
Show More Location
GSK Investigational Site
Learn More & Join Trial
A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 Years PHASE3 Human papillomavirus infection has clearly been recognized as the cause of ...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years PHASE3 Human papillomavirus infection has clearly been recognized as the cause of ...
Show More Location
GSK Investigational Site
Learn More & Join Trial